retapamulin

Therapeutic Classification: anti-infectives

Pharmacologic Classification: pleuromutilins

Indications ⬆ ⬇

REMS

Topical treatment of impetigo caused by methicillin-susceptible
Staphylococcus aureus
or
Streptococcus pyogenes
.

Action ⬆ ⬇

Interferes with bacterial protein synthesis at the level of the 50S ribosome.

Therapeutic effects:

Bacteriostatic action against susceptible organisms.

Pharmacokinetics ⬆ ⬇

Absorption: Minimal systemic absorption.

Distribution: Unknown.

Metabolism/Excretion: Small amounts absorbed are extensively metabolized.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

ROUTE	ONSET	PEAK	DURATION
Topical	Unknown	Unknown	12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

None.

Use Cautiously in:

OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Children 9 mo (safety and effectiveness not established).

Adv. Reactions/Side Effects ⬆ ⬇

Derm: application site irritation

Interactions ⬆ ⬇

Drug-drug:

Strong CYP3A4 inhibitors, including ketoconazole may ↑ levels; concomitant use not recommended in children <24 mo.

Route/Dosage ⬆ ⬇

(Adults and Children ≥9 mos): Apply thin layer to affected area (up to 100 cm² in adults or 2% total body area in children) twice daily for 5 days.

Availability ⬆ ⬇

Assessment ⬆ ⬇

Assess lesions before and daily during therapy.
Monitor for application site irritation (redness, itching, burning, swelling, blistering, oozing). Discontinue, wipe off ointment and use alternative therapy if irritation occurs.

Implementation ⬆ ⬇

Apply a thin layer to affected area twice daily for 5 days. May be covered with sterile bandage or gauze if desired; may protect from access by infants and young children or accidental transfer to eyes or other areas. Wash hands after application if hands are not area of treatment. Avoid oral, intranasal, ophthalmic, or intravaginal use.

Patient/Family Teaching ⬆ ⬇

Instruct patient or parent on correct application technique. Advise patient to apply medication exactly as directed for full course of therapy, even though symptoms have improved.
Teach patient and family appropriate hygienic measures to prevent spread of impetigo.
Instruct parents to notify school nurse for screening and prevention of transmission.
Advise patient to notify health care professional if application site irritation (redness, itching, burning, swelling, blistering, oozing) worsens or if there is no improvement within 3–4 days.

Evaluation/Desired Outcomes ⬆ ⬇

Healing of skin lesions.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

16110- Almirall, LLC
- 16110-518- Altabax
  - 16110-518-15- 1 TUBE in 1 CARTON (16110-518-15) > 15 g in 1 TUBE

16110- Almirall, LLC
- 16110-518- Altabax
  - 16110-518-30- 1 TUBE in 1 CARTON (16110-518-30) > 30 g in 1 TUBE

section name header

Pronunciation ⬇

Classifications ⬆ ⬇